Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Feline fibrosarcoma treatment to launch

New immunotherapeutic drug arriving in Autumn

It has been announced that the first immunotherapeutic cancer drug has been approved for veterinary use in Europe, and will launch in Autumn 2013.

The novel drug, Oncept IL-2, was unveiled by Merial R&D at a conference in Lisbon, as an innovative treatment for fibrosarcoma in cats.

A canarypox virus vector (ALVAC®) expressing Interleukin 2 (IL-2), has been selected for the treatment.

Hervé Poulet, R&D leader at Merial, explains: "It is very safe as it does not replicate and expresses IL-2 locally. It was found to be an efficacious adjunct treatment to surgery and radiotherapy."

During monocentric controlled trials of the drug, 71 cats with first occurrence fibrosarcoma were studied in three control groups.

One group received surgery and radiotherapy only, another also received low-dose IL-2 treatment, and the third received high-dose IL-2 alongside surgery and radiotherapy.

When treatment was given one day before the start of radiotherapy, it was found that the drug reduced the risk of relapse by 65 per cent compared to the control group, who received only surgery and radiotherapy.

Further, the median time for relapse rose from an average of 287 days to 730 days when the drug was administered, compared to when the drug was not used.

Presenting the results, Dr Dominique Jas of Merial R&D, said: "This study showed that the control group, that did not undergo immunotherapy, had poorer results than either treatment group – in spite of the cats receiving a total of thirty injections."

Merial's technical manager for companion animals, Catherine Pépin, added: “We’re very excited and proud to announce the forthcoming launch of a new immunotherapy, a recombinant canarypox virus expressing feline IL-2 at the site of injections."

Image from left: Pascal Fayard, Merial; Ana Lara, Royal Veterinary College; Herve Poulet, Merial R&D; Jolle Kirpensteijn, Utrecht University.

 

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
BSAVA announces 12th Edition of the Small Animal Formulary

The BSAVA has published an updated edition of its Small Animal Formulary, which includes new drug monographs and emergency drug doses for rabbits, rodents, birds and reptiles.

One of BSAVA's most trusted and widely used clinical resources, this 12th edition of the manual also includes seven new client information leaflets and information on drugs used for the management of urinary incontinence.

Part A of the Formulary, Canine and Feline, sees Fergus Allerton return as Editor-in-Chief, while Part B: Exotic Pets was edited by Joanna Hedley. For more information, visit the BSAVA website.